The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
Pharma exports in 2021-22 sustain a positive growth despite global trade disruptions
The plant is expected to start commercial operations from Q4FY24
Through the contract, the company will supply two key GMP intermediates for one of the 'patented drugs' of the innovator pharmaceutical customer
The company also plans to expand the facility
The expansion positions Cambrex with the largest and most advanced API facility in the United States
The new structure further transitions the Health Care business line into a system solutions partner for the pharmaceutical and biotech industries
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
A total of 49 projects have been approved so far for 33 critical APIs with a committed investment of Rs 3,685 crore
The capex during the last nine months has been around Rs 110 crores which is all funded through internal accruals
Subscribe To Our Newsletter & Stay Updated
